Cas:191739-36-3 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate manufacturer & supplier

Chemical Name:1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate

CAS.NO:191739-36-3

Synonyms:N,N-di-CBZ-2-carboxy-piperazine;1,4-bis(benzyloxycarbonyl)piperazine-2-carboxylic acid;piperazine-1,2,4-tricarboxylic acid 1,4-dibenzyl ester;1,4-di((benzyloxy)carbonyl)piperazine-2-carboxylic acid;N,N-bis-Cbz-2-carboxypiperazine;1,2,4-Piperazinetricarboxylic acid,1,4-bis(phenylmethyl) ester;(+/-)-N,N’-dibenzyloxycarbonylpiperazine-2-carboxylic acid

Molecular Formula:C₂₁H₂₁N₂O₆

Molecular Weight:397.40100

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:99.21000

Exact Mass:397.14000

LogP:1.27190

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N,N-di-CBZ-2-carboxy-piperazine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,(+/-)-N,N’-dibenzyloxycarbonylpiperazine-2-carboxylic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,1,4-di((benzyloxy)carbonyl)piperazine-2-carboxylic acid Use and application,piperazine-1,2,4-tricarboxylic acid 1,4-dibenzyl ester technical grade,usp/ep/jp grade.

Related News: Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women. 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate manufacturer Under the terms of this agreement, Inceptua will support Onconova through the pre-approval provision of intravenous rigosertib initially into a number of countries including: Australia, Denmark, Finland, France, Ireland, Italy, the Netherlands, Portugal, South Africa, Spain, and the UK. 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate supplier Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate vendor Analysts at Jefferies, meanwhile, said the FDA accelerated approval for Aduhelm, which was based on a surrogate endpoint of amyloid beta plaque reduction (and not clinical benefit) “has implications for ongoing AD studies,” most notably, it reckons, for Roche’s phase 3 GRADUATE test for its anti-amyloid-beta candidate gantenerumab, “as a much lower hurdle than demonstrating clear cognitive benefit” has now become precedent. Jefferies, still cautious, said it remains “unclear what stance FDA may take for the field if GRADUATE fails on cognition despite significant Abeta reductions,” but says it’s probably not going to revive Roche-AC Immune’s anti-amyloid-beta candidate crenezumab, which saw its late-stage CREAD trials discontinued for futility but which is currently in an Alzheimer’s prevention study. 1,4-bis(phenylmethoxycarbonyl)piperazine-2-carboxylate factory Of the nearly 4,000 Black women and more than 25,000 white women included in the study, there was no statistically significant difference in breast cancer-related genetic mutations. They were found in 5.65% of Black women and nearly 5.1% of white women.